Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


April 26, 2015 1:33 PM ET

Healthcare Providers and Services

Company Overview of Spotlight Innovation, Inc.

Company Overview

Spotlight Innovation, Inc. provides solutions for healthcare-focused companies commercializing healthcare intellectual property developed by centers of academia in the United States. It focuses on identifying, validating, and acquiring/cooperating with early stage companies developing healthcare technologies, including pharmaceuticals, devices and equipment, diagnostic products, and healthcare IT. The company, through its subsidiary, Celtic Biotech Iowa, Inc., also develops therapeutic products for the treatment of solid cancers and pain in humans. Spotlight Innovation, Inc. was founded in 2012 and is based in West Des Moines, Iowa.

6750 Westown Parkway

Suite 200-226

West Des Moines, IA 50266

United States

Founded in 2012

1 Employees

Phone:

515-274-9087

Key Executives for Spotlight Innovation, Inc.

Chief Executive Officer and Director
Age: 41
Total Annual Compensation: $116.6K
Compensation as of Fiscal Year 2013.

Spotlight Innovation, Inc. Key Developments

Spotlight Innovation, Inc. announced delayed annual 10-K filing

On 03/31/2015, Spotlight Innovation, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.

Celtic Biotech Iowa Licenses Promising Therapy for Chronic Kidney Disease

Spotlight Innovation Inc. announced that its subsidiary Celtic Biotech Iowa, Inc., entered into an exclusive, world-wide (excluding China) license agreement to develop and market a patent-pending invention related to the treatment of acute and chronic nephropathy, Use of Cardiotoxin for the Treatment of Chronic Kidney Disease (CKD). Animal studies have shown that cardiotoxin has the ability to inhibit the inflammatory immune processes that damage the kidneys, can reduce the level of proteinurea, serum creatinine and urea in chronic neuropathy, and recover renal function and reduce renal injury.

Spotlight Innovation, Inc. announced delayed 10-Q filing

On 11/14/2014, Spotlight Innovation, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.

Similar Private Companies By Industry

Company Name Region
Total Sleep Holdings, Inc. United States
Pine Grove Ambulatory Surgical Center LLC United States
Utah Surgery Center, L.P. United States
US Cannabis, Inc. United States
USC Norris Cancer Hospital United States

Recent Private Companies Transactions

Type
Date
Target
Private Placement
March 31, 2015
--
Merger/Acquisition
October 14, 2014
Memcine Pharmaceuticals Inc.
Private Placement
June 9, 2014
--
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Spotlight Innovation, Inc., please visit www.spotlightinnovation.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.